Aardvark Therapeutics, Inc.
AARD
$4.18
-$0.36-7.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 117.20% | 217.36% | 286.55% | 32.24% | 181.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 114.56% | 97.93% | 247.73% | 160.96% | 382.27% |
| Operating Income | -114.56% | -97.93% | -247.73% | -160.96% | -382.27% |
| Income Before Tax | -131.88% | -100.46% | -290.15% | -163.66% | -327.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -131.88% | -100.46% | -290.15% | -163.66% | -327.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -131.88% | -100.46% | -290.15% | -163.66% | -327.46% |
| EBIT | -114.56% | -97.93% | -247.73% | -160.96% | -382.27% |
| EBITDA | -114.55% | -97.99% | -247.72% | -160.86% | -382.48% |
| EPS Basic | -40.24% | 62.61% | 28.36% | 51.76% | -28.52% |
| Normalized Basic EPS | -40.38% | 62.45% | 26.60% | 52.05% | -35.14% |
| EPS Diluted | -40.24% | 62.61% | 28.36% | 51.76% | -28.52% |
| Normalized Diluted EPS | -40.38% | 62.45% | 26.60% | 52.05% | -35.14% |
| Average Basic Shares Outstanding | 65.34% | 436.11% | 444.62% | 446.63% | 232.59% |
| Average Diluted Shares Outstanding | 65.34% | 436.11% | 444.62% | 446.63% | 232.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |